New Brunswick

Sandoz Canada Congratulates the Quebec Government on Implementing a Shift Towards Biosimilars

Shots: Quebec will follow a similar approach to policies introduced in British Columbia, Alberta and recently in New Brunswick to transition patients who use a reference biologic to a biosimilar. This will contribute to annual savings that can be reinvested in healthcare and innovative new drugs The transition will take place under the supervision of …

Sandoz Canada Congratulates the Quebec Government on Implementing a Shift Towards Biosimilars Read More »

J&J to buy Momenta Pharmaceuticals for $6.5B

The drugmaker emphasized the full global rights it would acquire to Momenta’s lead asset, nipocalimab, which it is developing for several autoantibody-driven diseases and that in certain indications could have peak sales of more than $1 billion.